SABS

SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of human polyclonal immunotherapeutic antibodies, or human immunoglobulin G (hIgG), to address immunology disorders. The Company is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets or best-in-class against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders. The Company’s lead product candidate, SAB-142, is a human anti-thymocyte globulin (ATG) focused on preventing or delaying the progression of T1D. SAB-142 is expected to reduce autoimmune beta cell destruction and delay progression or onset of T1D in patients with Stage III or Stage II T1D. The Company’s genetic engineering platform produces human, multi-targeted, high-potency immunoglobulins, without the need for human donors or convalescent plasma.

Wall Street analysts forecast SABS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SABS is 8.00 USD with a low forecast of 7.00 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

SAB Biotherapeutics Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

SAB Biotherapeutics Inc. EPS for the last quarter amounts to -0.21 USD, decreased -81.25 % YoY.

SAB Biotherapeutics Inc (SABS) has 63 emplpoyees as of December 16 2025.

Today SABS has the market capitalization of 190.43M USD.